Cyproterone acetate
- Generic Name
- Cyproterone acetate
- Brand Names
- Androcur, Cléo -35, Cyestra-35, Diane
- Drug Type
- Small Molecule
- Chemical Formula
- C24H29ClO4
- CAS Number
- 427-51-0
- Unique Ingredient Identifier
- 4KM2BN5JHF
- Background
An anti-androgen that, in the form of its acetate (cyproterone acetate), also has progestational properties. It is used in the treatment of hypersexuality in males, as a palliative in prostatic carcinoma, and, in combination with estrogen, for the therapy of severe acne and hirsutism in females.
- Indication
For the palliative treatment of patients with advanced prostatic carcinoma.
- Associated Conditions
- Menstrual Irregularities, Osteoporosis, Paraphilia, Postmenopausal Osteoporosis, Primary Amenorrhoea, Secondary Amenorrhea, Severe Acne, Advanced carcinoma of the prostate, Metastatic Carcinoma of the Prostate
- Associated Therapies
- Hormone Replacement Therapy
A contemporary review of the management strategies for sickle cell disease related
Patient education, lifestyle modifications, and medication review are crucial for managing priapism in sickle cell disease (SCD). Alpha-adrenergic agonists like etilefrine and phosphodiesterase type 5 inhibitors (PDE5i) are used to treat SCD-related priapism. Hormonal manipulation with cyproterone acetate, 5-α reductase inhibitors, ketoconazole, and diethylstilbestrol shows limited efficacy. Hydroxyurea, red cell exchange therapy, crizanlizumab, voxelotor, and L-glutamine offer potential benefits but lack specific trials for priapism. Allogeneic hematopoietic stem cell transplantation and gene therapy are curative options with ongoing research.
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
© Copyright 2024. All Rights Reserved by MedPath